As the debate over a draft resolution supporting greater price transparency for medicines in national and global markets intensifies, with closed-door consultations among countries at the 72nd World Health Assembly continuing late into the night, Health Policy Watch continues to feature diverse “Inside Views” on this charged issue. Here, Suerie Moon, MPA PhD, faculty member […] Continue reading ->
[Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading ->
Health is about political leadership, partnership and people, Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, said today in his opening address of the 72nd World Health Assembly in Geneva, adding that these three priorities must guide discussions not only this week, but throughout the next year. Image Credits: WHO/Laurent Cipriani. Continue reading ->
Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading ->